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Alternative reading frame (ARF) is a tumor suppressor protein that senses oncogenic and
other stressogenic signals. It can trigger p53-dependent and -independent responses
with cell cycle arrest and apoptosis induction being the most prominent ones. Other
ARF activities, particularly p53-independent ones, that could help in understanding cancer
development and provide potential therapeutic exploitation are underrated. Although ARF
is generally not expressed in normal tissues, it is essential for ocular and male germ
cells development. The underlying mechanism(s) in these processes, while not clearly
deﬁned, point toward a functional link between ARF, DNA damage and angiogenesis.
Based on a recent study from our group demonstrating a functional interplay between
ataxia-telangiectasia mutated (ATM) and ARF during carcinogenesis, we discuss the role
of ARF at the crossroads of cancer and developmental processes.
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INTRODUCTION
The ARF (p14ARF in humans, p19ARF in mice) tumor suppres-
sor is encoded by the INK4A/ARF locus that also harbors another
onco-suppressor, namely the cyclin-dependent kinase inhibitor
p16INK4A (Quelle et al., 1995; Sherr, 2006). The p16INK4A pro-
tein maintains pRB in an active form to inhibit E2F activity
(Tsantoulis and Gorgoulis, 2005; Sherr, 2006). In this way S-phase
entry and therefore cell division is prevented (Sherr, 2006). On
the other hand, ARF is a “sensor” of various stresses includ-
ing oncogenic ones, like aberrant expression of Myc, E1A and
RAS (de Stanchina et al., 1998; Zindy et al., 1998; Palmero et al.,
1999). Other stresses that can also activate ARF are oxidative
stress and heat shock (Damalas et al., 2011; Liontos et al., 2012).
In response it can act both in p53-dependent and -independent
manners (Weber et al., 2000; Kotsinas et al., 2014), triggering
either growth arrest or apoptosis to counteract abnormal cell
proliferation (Sherr, 2006). Apart from cancer (Sherr, 2006), accu-
mulating data highlight ARF as a versatile protein implicated
in various physiological processes including developmental ones
Abbreviations: ARF, alternative reading frame; ATM, ataxia-telangiectasia mutated;
DDR, DNA damage response; DMSO, dimethyl sulfoxide; DSBs, doubled-strand
breaks; FSH, follicle-stimulating hormone; HA, hyaloid artery; HIF1α, hypoxia-
inducible factor 1α; HR, homologous recombination; HVS, hyaloid vascular system;
IRES, internal ribosome entry sequence; LH, luteinizing hormone; MEFs, mouse
embryonic ﬁbroblasts; MVD, microvessel density; NPM/B23, nucleophosmin;
NSCLC, non-small cell lung cancer; P, postnatal day; PDGFβ, platelet-derived
growth factor β; PDGFRβ, platelet-derived growth factor receptor β; PHPV, persis-
tent hyperplastic primary vitreous; pRb, retinoblastoma protein; sh, short-hairpin;
VEGF, vascular endothelial growth factor; YFP, yellow ﬂuorescent protein.
(Thornton et al., 2005; Gromley et al., 2009; Churchman et al.,
2011), immunomodulation (Través et al., 2012) and ribosomal
ribonucleic acid (rRNA) maturation (Sugimoto et al., 2003),
as well as pathological ones, such as atherogenesis (González-
Navarro et al., 2010). Most of the best known ARF functions are
p53-dependent ones (Sherr, 2006), while independent activities
seem to be underrated.
Deﬁciency of ARF or p53, has revealed different phenotypes
in mice. Speciﬁcally, ARF-null animals mainly develop sarco-
mas, whereas p53-null animals are predominantly characterized
by the evolvement of lymphomas (Kamijo et al., 1999). This
ﬁnding was among the ﬁrst experimental indications that ARF
and p53 can signal independently of each other and not neces-
sarily in a strict linear signaling pathway. Therefore, they may
fulﬁll different tasks in tumor surveillance. Moreover, recent
evidence from our group has highlighted the functional sig-
niﬁcance of a cross-talk among ARF and ATM (Velimezi et al.,
2013; Kotsinas et al., 2014) and how ARF can act as an “auxil-
iary” tumor suppressive mechanism throughout cancer progres-
sion in case the DDR pathway is compromised (Velimezi et al.,
2013).
In various normal tissues ARF is not expressed. Striking
exceptions are the developing oculus (eye), testicular tissue and
umbilical arteries (Thornton et al., 2005; Freeman-Anderson et al.,
2009; Gromley et al., 2009; Churchman et al., 2011). The underly-
ing mechanism(s) taking place in these tissues, while not clearly
deﬁned, point toward a functional link betweenARF,DNAdamage
and angiogenesis.
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Considering the ATM and ARF interplay in carcinogenesis
(Velimezi et al., 2013), we discuss in this article the role of ARF at
the crossroads of cancer and developmental processes. We present
the current knowledge regarding the role of ARF in development,
particularly during spermatogenesis and ocular development in
mice. Furthermore, we provide data (including unpublished
ones) consolidating the notion that the interference with vas-
cular dynamics accounts for a novel, inherent p53-independent
tumor suppressive property of ARF that could be therapeutically
exploited in p53-deﬁcient tumors.
THE ROLE OF ARF IN MALE GERM CELL DEVELOPMENT: A
MATTER OF PRESERVING GENOMIC INTEGRITY
Spermatogenesis is a spatio-temporally coordinated process by
which undifferentiated spermatogonia (i.e., the stem cell pop-
ulation of germinal cells residing on the basement membrane
of semiferous tubules) evolve into spermatocytes in the lumen
through a series of mitotic and meiotic cellular divisions (Cooke
and Saunders, 2002). In mice, Gromley et al. (2009) reported
that in this developmental process ARF is selectively expressed in
mitotic spermatogonia, but not in intratubular spermatocytes that
stain positive for meiotic markers (Figure 1). Intriguingly, in the
absence of ARF the testicles of mice exhibit atrophy and produce
much lower quantity of sperm compared to wild-type animals.
These phenotypic changes are accompanied by increased levels
of apoptosis in germ cells during all their developmental stages.
Of note, abolishment of this transient expression of ARF during
spermatogenesis is sufﬁcient to compromise this developmental
process throughout the whole reproductive life of mice (Gromley
et al., 2009).
Subsequent experiments carried out by the same research group
demonstrated thatARF is essential for normal meiotic progression
and survival of spermatocytes via initiation of a feed-forward pro-
gram in their progenitors, the spermatogonia. Interestingly, ARF
expression in spermatogonia did not exert an anti-proliferative
effect, as they also expressed cyclin D1. Testicular atrophy and
reduced production of mature sperm in ARF-deﬁcient mice was
not mechanistically related to a disturbed pituitary-gonadal axis
and deregulated levels of circulating FSH or LH. Rather, in the
absence of ARF a marked increase in the number of spermatocytes
undergoing p53-dependent apoptosis at the stage of pachytene of
prophase I was observed (Churchman et al., 2011).
Of note, during HR in meiosis the topoisomerase-II like Spo11
enzyme normally causes DSBs, which in turn trigger the activation
of ATM and the generation of γ-H2AX foci selectively at the lep-
totene and zygotene stages (Inagaki et al., 2010). At the pachytene
stage when synapsis of homologous chromosomes has been com-
pleted, γ-H2AX foci are normally not detected. However, in situ
analyses showed that in an ARF deﬁcient background, the num-
ber of γ-H2AX foci in pachytene spermatocytes is signiﬁcantly
increased (Churchman et al., 2011). The latter observation was
therefore suggestive of meiotic defects that have deleterious effects
on spermatocytic genomic integrity. Additional evidence for mei-
otic abnormalities included the identiﬁcation of asynaptic regions
as well as decreased number of foci of the Rad51 andDmc1 recom-
binases known to be associated with the repair of DSBs that occur
during HR. Overall, the authors concluded that ARF through a
yet poorly understood mechanism, interferes with HR to preserve
the ﬁdelity of meiosis in spermatocytes and to protect them from
DNA damage and p53-dependent apoptosis (Churchman et al.,
2011). Whether the apoptotic death of spermatocytes is a conse-
quence of DNA damage per se or not, remains to be elucidated.
Inhibition rather than induction of p53-dependent apoptosis by
ARF is a unique feature of male germ cells and reveals an opposite
to the well-established p53-mediated pro-apoptotic role of ARF in
somatic cells (Lowe and Sherr, 2003).
Importantly, ARF is not the only DNA damage-related pro-
tein that interferes with the spermatogonial program (Figure 1).
The DDR kinase ATM is actually essential for the maintenance of
undifferentiated spermatogonia and for retaining their stemness
(Barlow et al., 1998; Takubo et al., 2008). In murine testicles, ATM
deﬁciency progressively results in the depletion of undifferenti-
ated spermatogonia. This is functionally associated with cell cycle
arrest, loss of genomic integrity and defects at the pre-meiotic
level (Barlow et al., 1996, 1998; Elson et al., 1996; Xu et al., 1996;
Takubo et al., 2008). Mechanistically, the absence of ATM is linked
to the accumulation of DNA damage and the activation of an
ARF/p53/p21WAF1/Cip1 – dependent growth restrictive pathway.
Notably, in transplantation assays where spermatogonia are deliv-
ered into the seminiferous tubules of mutant mouse strains that
exhibit defective spermatogenesis, p21WAF1/Cip1 deﬁciency is able
to restore spermatogonial repopulation ability in an ATM-null
background (Takubo et al., 2008).
Taken together, all the above data pinpoint that both ARF and
ATM are critical factors for the maintenance of spermatogonia
and survival of their progeny during male germ cell development
(Figure 1; Barlow et al., 1996; Takubo et al., 2008; Churchman
et al., 2011). This common feature parallels with their same func-
tion as tumor suppressors in somatic cells. Nevertheless, the
imposed outcomes are different in each cell type, suggesting a
functional bimodality. In somatic cells ATM and ARF induce cell
growth restrictive or apoptotic routes, whereas in spermatogo-
nia they do not interfere with their ability to proliferate. It is
rather their depletion that leads to such cellular responses. A fur-
ther issue, stemmed from the ability of ATM to regulate ARF
turnover (Velimezi et al., 2013), is whether this functional link
may operate in male germ cells. As demonstrated, in response
to irradiation ARF protein in spermatogonia is markedly down-
regulated (Velimezi et al., 2013). Evidence was also provided by
Takubo et al. (2008) showing that in ATM null spermatogonia
there is a higher activation of ARF, supporting the intercon-
nection between ATM and ARF. Nevertheless, details on how
this link endorses this developmental process require further
clariﬁcations.
ARF AS A REGULATOR OF THE VASCULAR NETWORK IN
DEVELOPMENT AND TUMORIGENESIS
Apart from the male germ cell development in mice as presented
above, ARF also plays a central role in the murine ocular develop-
ment. In mice models it was shown that ARF is required for the
maturation of the primary vitreous into the secondary vitreous;
an avascular jelly like substance within the developing oculus. The
expression of ARF in the vitreous is postnatally induced up to P5,
in order to trigger the involution of HVS, a transient anatomical
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FIGURE 1 | Schematic presentation of the spermatogenesis stages
across the wall of a seminiferous tubule and the interrelations with
ATM and ARF. (A) Spermatogonia are found in close proximity to the
basement membrane of a seminiferous tubule. A subpopulation of
spermatogonia exhibits stem cell ability and self-renews via mitotic
divisions. ATM kinase is essential for their stemness (symbolized by a
semicircular shape). Some of the spermatogonia eventually differentiate into
primary spermatocytes. The latter, undergo meiosis to give rise to
secondary spermatocytes which in turn, form spermatids (connected via
cytoplasmic bridges). Spermatids engage a series of cytodifferentiative
programs and sperm is ﬁnally formed. ARF expression in spermatogonia is
required in order to prevent the occurrence of DNA damage in meiotic
primary spermatocytes (at the stage of pachytene) through participating in a
feed-forward program. (B) In the absence of ARF, genomic integrity in
primary spermatocytes is threatened and the production of mature sperm
released in the lumen is compromised. (C) Upon ATM deﬁciency,
spermatogonia loose their genomic integrity and ARF undergoes
upregulation. Consequently, an ARF-mediated p53/p21WAF1/Cip1 growth
restrictive pathway counteracts spermatogonial stemness. Due to the fact
that ATM deﬁciency hampers normal spermatocytic meiotic progression (at
prophase I), sperm production is compromised (Barlow et al., 1996, 1998;
Xu et al., 1996). The different subtypes of spermatogonial cells, Sertoli cells
that support spermatogonia, stages and phases of meiosis, the different
stages of spermatid differentiation as well as ploidy of cells are not shown
here for reasons of simplicity (Colored lines depict ATM and/or ARF effects
on spermatogenesis. Dashed colored lines denote weak effect or weak
activation. Red lines represent adverse effect, while green ones correspond
to physiologic functions).
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entity in the developing oculus that has to regress during P6–P10
(McKeller et al., 2002). ARF promotes HVS involution through
restricting the accumulation of mural cells that cover the vessels
and contributes to the preservation of their stability in a PDGFRβ-
dependent/p53-independent manner (Silva et al., 2005; Gromley
et al., 2009). Overall, two models have been proposed to explain
the mechanistic basis by which ARF controls the vascular network
dynamics. According to the ﬁrst model, when ARF is induced
by unknown yet upstream developmental signals it suppresses
PDGFRβ expression via uncharacterized mediators. In this way,
ARF restricts mural cell proliferation. In the second scenario, ARF
acts as a cell fate determinant during the maturation of mural cells
to shut off PDGFRβ expression and force them to differentiate
into a type of perivascular cells that selectively support transient
vessels (Thornton et al., 2005).
Notably, phenotypic characteristics exhibited by ARF deﬁ-
cient mice are also found in the developmental human ocular
disease termed PHPV and include microphthalmia and degener-
ative alterations in lens (cataractogenesis; McKeller et al., 2002).
Overall, these data pinpoint to the existence of an ARF-mediated
tightly regulated spatio-temporal angiogenic developmental pro-
cess. It appears that ARF’s role in vascular evolvement is not
solely restricted to developmental processes. Rather, data corrob-
orate the notion that ARF exhibits a wider activity in the control
of vascular dynamics, which are functionally linked to tumor
progression.
“Angiogenic switch” is a prominent feature of tumor progres-
sion (Bergers and Benjamin, 2003). In line with the notion that
ARF plays a wide role in the modulation of pathways affecting vas-
culature, an inverse correlation among MVD and ARF in human
clinical colon cancer samples has been reported (Kawagishi et al.,
2010). Furthermore, ARF/p53 deﬁcient MEFs challenged with
oncogenic RASV12 when injected as xenografts produce tumors
that grow faster relative to similarly treated cells, but retrovirally
infectedwithARF (Kawagishi et al., 2010). Tumor sections showed
in the latter case a lower immunostaining for CD31, a neovas-
cular marker. Exploring mechanistically their ﬁndings Kawagishi
et al. (2010) determined that ARF suppresses the expression of
VEGFA in a p53-independent manner in mouse cell lines. This
involves the inhibition of VEGFA translation via the IRES of
VEGFA.
Based on our recent ﬁnding that ATM controls ARF turnover
(Velimezi et al., 2013), we sought to expand these observations
in human tumors with inactive p53 and explore for potential
therapeutic utilization. Treating the NSCLC cell line H1299 and
cervical carcinoma HeLa cells, which do not express functional
p53, with the ATM kinase inhibitor Ku55933 in order to stabilize
ARF (Velimezi et al., 2013) we observed an inverse relationship
among the expression of ARF and VEGF protein (Figure S1A).
VEGF plays a central role in tumor angiogenesis (Crinò and
Metro, 2014), while ARF can signal in a p53-independent fash-
ion and hence, serve as a “back-up” barrier to tumorigenesis
in case that p53 is inactivated (Velimezi et al., 2013). Therefore,
upregulating ARF via inhibition of ATM activity may be exploited
in p53-deﬁcient human tumors as a novel anti-angiogenic ther-
apeutic approach. In a next step, we investigated whether ARF
opposes tumor angiogenesis in vivo. To address this issue H1299
cells were xenografted in immunocompromised mice. Sections
from the generated tumors were stained with an antibody spe-
ciﬁc for the endothelial marker CD31, to evaluate MVD. As
shown in Figure S1B, MVD is markedly decreased (>twofold)
in tumors injected with a lentiviral vector expressing shRNA tar-
geting ATM (ctl-shRNA/Lenti-shATM); a manipulation which
upregulates ARF (Velimezi et al., 2013). The observed reduc-
tion in MVD was actually an ARF-dependent phenomenon,
because MVD in H1299-shARF xenografts upon knocking down
of ATM (shARF/Lenti-shATM) was found to be comparable
to that estimated in ARF-expressing ones without lentivirus-
mediated silencing of ATM kinase (ctl-shRNA/Lenti-ctl). There-
fore, stabilization of ARF in the absence of ATM activity exhibits
anti-angiogenetic effects in vivo, corroborating the claim that
this p53-independent ATM/ARF axis could be therapeutically
harnessed.
In our experiments we did not examine whether the observed
ARF-mediated down-regulation of VEGF levels is associated
with an inhibition of IRES-(in)dependent translation of VEGF
transcript (Kawagishi et al., 2010), or if it is due to a translation-
independent mechanism. For instance, HIF1α is a well-known
transcriptional activator of VEGF and human ARF has been
demonstrated to mediate the nucleolar sequestration of HIF1α,
thereby hindering its ability to drive the expression of its target
genes (Fatyol and Szalay, 2001). It would be a challenging future
task to uncover the whole mechanistic spectrum that underlies the
observed mutual exclusive expression among ARF and VEGF.
In a murine model of multi-stage pancreatic neuroendro-
crine tumorigenesis where the SV-40 T-antigen is expressed in
β cells, ARF deﬁciency was found to signiﬁcantly accelerate tumor
progression through promoting the angiogenic switch (Ulanet
and Hanahan, 2010). In the absence of ARF the tumor burden
was increased ﬁvefold along with a higher number of angio-
genic lesions. From a mechanistic perspective, in this malignancy
ARF seems to act via engaging mainly p53-independent routes,
while VEGF was not involved (Ulanet and Hanahan, 2010). A
more recent study showed that ARF blocks the development of
angiosarcomas associated with the exposure to the carcinogen
urothene, possibly in a p53-dependent fashion (Busch et al., 2012).
Intriguingly, it was hypothesized that ARF affects the prolifera-
tion of endothelial cells in adult mice. Hence, the inhibition of
tumor angiogenesis and vascular malignancy possibly represent
two discrete aspects of ARF’s tumor-suppressive activity.
CONCLUSIONS AND PROSPECTS
Collectively, we highlight underrated functions of ARF, posi-
tioned at the crossroads of tumor suppression (Weber et al.,
2000; Tago et al., 2005; Kawagishi et al., 2010) and development
(McKeller et al., 2002; Churchman et al., 2011; Figure 2), that
could be exploited at the therapeutic level, especially in tumors
with non-functional p53.
ARF as an onco-suppressor impedes carcinogenesis not
only through interfering with cell proliferation and induc-
tion of apoptosis, but also via affecting other cancer-
promoting processes such as angiogenesis (Kawagishi et al., 2010;
Ulanet and Hanahan, 2010). In this context, in tumors with non-
functional p53 the potential to upregulate ARF in anATM manner
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FIGURE 2 | ARF impinges both on developmental processes (male
germ cell development and ocular development in mice) and
tumor angiogenesis. ARF is essential for normal spermatogenesis in
mice possibly through interacting with the meiotic repair machinery. In
the ocular development of the mouse, ARF is required for the
involution of the hyaloid vascular system (HVS); a transient network of
vessels that provides nutrients to the developing oculus. This is
accomplished via a pathway in which ARF blocks platelet-derived
growth factor receptor β (PDGFRβ)-dependent signaling which in turn,
is necessary for the investment of vessels by mural cells and their
maintenance. This may also be possibly regulated via the
ARF-dependent inhibition of internal ribosome entry site
(IRES)-mediated translation of PDGFRβ. ARF can also suppress the
IRES-mediated translation of vascular endothelial growth factor A
(VEGFA), thereby inhibiting tumor angiogenesis. Unpublished data
indicate that the stabilization of endogenous ARF upon inhibition of
ataxia-telangiectasia mutated (ATM) kinase activity can also result in a
decrease in VEGF levels; although it is not known whether the
underlying mechanism involves the suppression of IRES-mediated
translation of VEGF or an IRES-independent route. It may even involve
a route that is not associated with the control of VEGF at the
translational level. (The ATM/ARF/VEGF pathway is shown by lines.)
ATM kinase itself, independently of ARF, has also been incriminated in
pathological angiogenesis in adult mouse oculus and cancer (Kerr and
Byzova, 2012), but these effects are not depicted here for reasons of
clarity. (HA, hyaloid artery.)
(Velimezi et al., 2013), could be utilized as an anti-angiogenic
“tool” in cancer management (Figure S1). This prospective thera-
peutic modality may be enhanced if combined with anti-VEGF or
other anti-angiogenic factors, like tyrosine kinase inhibitors, that
are currently used (Ferrara et al., 2004; Randall and Monk, 2010;
Eisen et al., 2012). On one hand, such a dual treatment might lead
to a synergistic outcome, possibly lethality, and on the other hand,
it may allow the reduction of the administration doses of such
compounds to avoid side-effects (Randall and Monk, 2010; Eisen
et al., 2012). It should be noted that although the ATM inhibitor
Ku55933 is highly selective toward ATM, its bioavailiability is low
due to its pharmacokinetic properties (Golding et al., 2009). How-
ever, new ATM inhibitors, such as KU-60019, exhibiting a higher
pharmacological proﬁle have been released (Golding et al., 2009),
rendering the proposed therapeutic approach feasible.
Another option in order to therapeutically exploit the afore-
mentioned ARF/VEGF pathway would be the usage of synthetic
ARF peptides comprising ARF’s amino-terminal residues 2–14
that mediate all the biological effects of ARF, including the anti-
growth ones (Saporita et al., 2007). The therapeutic exploitation
of the p53-independentARF/VEGF axis is of major clinical impor-
tance since p53 is inactivated in ∼50% of human cancers (Sherr,
2006).
A further aspect that needs to be addressed is the role of ARF
in spermatogenesis. Deciphering the poorly deﬁned ability of ARF
to cross-talk with components of the HR mechanism during this
process could provide new insights on other underrated functions
of ARF. Speciﬁcally, in the case of male germ cells ARF contributes
to their genomic integrity during their maturation, but the exact
mechanism(s) is still lacking (Churchman et al., 2011). Even more,
as ATM also participates in this process and since they are func-
tionally linked (Velimezi et al., 2013), the exact way their function
is coordinated throughout this process remains to be deﬁned.
Finally, taking into consideration the role of ARF not only in
the involution of HVS in the developing oculus (Thornton et al.,
2005) but also in the involution of the mammary gland (Yi et al.,
2004), it is plausible thatARFplays an evenwider role than that of a
tumor suppressor by acting as a potent “tissue remodeling factor”
controlling transient histological structures. Studies toward this
direction are essential and could open a new research ﬁeld related
with ARF.
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abstract
Figure S1 | ARF demonstrates a p53-independent anti-angiogenic activity
in a malignant environment. (A) Evidence for a p53-independent
ATM/ARF/VEGF pathway. Human ARF protein (mouse monoclonal antibody,
1:100 dilution, DCS-240, #ab49166, Abcam) was up-regulated in the presence
of the selective ATM inhibitor Ku55933 (Ku, #118500, Calbiochem, MERCK) and
as previously shown biologically effective (Velimezi et al., 2013). This was
associated with a decrease in VEGF protein (rabbit polyclonal antibody, 1:100
dilution, A-20, #sc-152, SantaCruz) levels as assessed by immunoblot analysis in
human cancer cells H1299 and HeLa, both of which are devoid of functional
p53. Actin (rabbit polyclonal antibody, 1:1000 dilution, Cell Signaling Technology
Inc., #4967) served as a loading control. (ATMi: treatment with the Ku55933
chemical inhibition of ATM activity). (B) ARF-dependent decreased microvessel
density in a malignant environment. The non-small cell lung cancer (NSCLC)
cells H1299, which do not express a functional p53 were xenografted in
immunocompromised mice and formed tumors (Velimezi et al., 2013).
Immunohistochemical (IHC) analysis was carried out using an anti-CD31
antibody in order to evaluate mean microvessel density (MVD) in sections from
tumor tissue. MVD is more than twofold decreased in tumors that were
injected with a lentiviral vector expressing short-hairpin (sh) RNA targeting ATM
(ctl-shRNA/Lenti-shATM) where ARF is known to be upregulated. On the
contrary, the MVD in H1299-shARF xenografts, where ATM has been silenced
(shARF/Lenti-shATM), is not decreased. Rather, it is comparable to those
estimated in ARF-expressing xenografts without lentivirus-mediated silencing of
ATM kinase (ctl-shRNA/Lenti-ctl).
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